U S Gulf Coast Trading Co., Inc.
Letter data
- Company
- U S Gulf Coast Trading Co., Inc.
- Recipient
- Abdallah K. Yassir | Managing Partner and Co-Owner | U S Gulf Coast Trading Co., Inc. | 14100 Auto Park Way Ste. I | Houston | , | TX | 77083-6656 | United States
- Issue date
- 2024-07-11
- Posted date
- Not available
- FDA office
- Division of Human and Animal Food Operations West III
- Subject
- Not available
- Product
- Food & Beverages
- CMS ID
- 668767
- Reference number
- Not available
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
U S Gulf Coast Trading Co., Inc.
MARCS-CMS 668767 —
July 11, 2024
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Product:
Food & Beverages
Recipient:
Recipient Name
Abdallah K. Yassir
Recipient Title
Managing Partner and Co-Owner
U S Gulf Coast Trading Co., Inc.
14100 Auto Park Way Ste. I
Houston
,
TX
77083-6656
United States
Issuing Office:
Division of Human and Animal Food Operations West III
United States
Secondary Issuing Offices
United States
Dear Mr. Yassir,
The Food and Drug Administration has completed an evaluation of your corrective actions in response to our Warning Letter dated December 5, 2023, issued following inspection of your facility located at 14100 Auto Park Way, Suite I, Houston, TX 77083-6656. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. If you choose to reestablish or sell your operations, the Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Dana Lewis
Acting Director, Compliance Branch
Office of Human and Animal Food, WD3
Content current as of:
07/17/2024
Regulated Product(s)
Food & Beverages